RCS - Moolec Science SA - Moolec Science Secures Up to $50 Million

Moolec Science SaAnnouncement

18/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230418:nRSR5579Wa&default-theme=true

RNS Number : 5579W  Moolec Science SA  18 April 2023

Moolec Science Secures Up to $50 Million in Committed Equity Financing With
Nomura

LUXEMBOURG / ACCESSWIRE / April 17, 2023 / Moolec Science SA (NASDAQ:MLEC)
("Company"; "Moolec"), a science-based food ingredient company focused on
producing animal proteins in plants through Molecular Farming, announced today
it has entered into a Share Purchase Agreement ("Agreement") with Nomura
Securities International, Inc. ("Nomura").

The Agreement provides for a committed equity financing facility under which
the Company has the option, but not the obligation, to sell up to the
equivalent of $50 million in aggregate gross purchase price of its ordinary
shares to Nomura over a 36-month period, subject to the terms of the
Agreement. The Company intends to use the proceeds from any future sales of
securities under the financing facility, if it is utilized, for general
corporate purposes.

"We are pleased to partner with Nomura and secure this financing facility,"
said José López Lecube, Moolec Science's Chief Financial Officer. "This new
understanding provides Moolec with enhanced financial flexibility to continue
driving forward our Molecular Farming Platform and portfolio of products," he
concluded.

Further details are contained in a Current Report on Form 6-K that was filed
with the Securities and Exchange Commission today.

About Moolec Science SA

Moolec is a science-based food ingredient company focused on producing animal
proteins in plants through Molecular Farming, a disruptive technology in the
alternative protein landscape. Its purpose is to upgrade the taste, nutrition,
and affordability of alternative protein products while building a more
sustainable and equitable food system. The Company's technological approach
aims to have the cost structure of plant-based solutions with the organoleptic
properties and functionality of animal-based ones. Moolec's technology has
been under development for more than a decade and is known for pioneering the
production of a bovine protein in a crop for the food industry. The Company's
product portfolio and pipeline leverages the agronomic efficiency of broadly
used target crops, like safflower, soybean, and pea. Moolec has a growing
international patent portfolio (23, both granted and pending) for its
Molecular Farming technology. The Company is run by a diverse team of Ph.Ds
and Food Insiders, and operates in the United States, Europe, and South
America. For more information, visit www.moolecscience.com
(https://pr.report/G-z8QUNA) .

Forward-Looking Statements

This press release contains "forward-looking statements." Forward-looking
statements may be identified by the use of words such as "forecast," "intend,"
"seek," "target," "anticipate," "believe," "expect," "estimate," "plan,"
"outlook," and "project" and other similar expressions that predict or
indicate future events or trends or that are not statements of historical
matters. Such forward-looking statements with respect to performance,
prospects, revenues, and other aspects of the business of Moolec Science S.A.
("Moolec") are predictions, projections and other statements about future
events that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Although we believe that we
have a reasonable basis for each forward-looking statement contained in this
press release, we caution you that these statements are based on a combination
of facts and factors, about which we cannot be certain. We cannot assure you
that the forward-looking statements in this press release will prove accurate.
These forward-looking statements are subject to a number of significant risks
and uncertainties that could cause actual results to differ materially from
expected results, including, among others, changes in applicable laws or
regulations, the possibility that Moolec may be adversely affected by
economic, business and/or other competitive factors, costs related to the
scaling up of Moolec's business and other risks and uncertainties, including
those included under the header "Risk Factors" in the Form F-1 Registration
Statement filed with the U.S. Securities and Exchange Commission ("SEC"), as
well as Moolec's other filings with the SEC. Should one or more of these risks
or uncertainties materialize, or should any of our assumptions prove
incorrect, actual results may vary in material respects from those projected
in these forward-looking statements. We undertake no obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required under applicable
securities laws. Accordingly, you should not put undue reliance on these
statements.

Contact Information

Catalina Jones

Chief of Staff & Sustainability
comms@moolecscience.com (mailto:comms@moolecscience.com)

Martín Taraciuk

Investor Relations
ir@moolecscience.com (mailto:ir@moolecscience.com)

Michael Bowen

ICR, LLC
moolecir@icrinc.com (mailto:moolecir@icrinc.com)

Related Files

Moolec Science Secures up to $50 Million Dollars in Committed Equity Financing
with Nomura - 2023.04.17.pdf (https://pr.report/s9aKFbg-)

SOURCE: Moolec Science

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGZGMDFRNGFZG